Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 9, Issue 10 (2020)

A study of serum vascular endothelial growth factor and APO-A1 in diabetes mellitus with retinopathy

Author(s):
Arunava Sarkar, Ranjan Bhattanagar and Ravi Tandon
Abstract:
Background: The present study is aimed to look into the status of serum VEGF and APO A-1 in the patients of type II diabetes with retinopathy without hypertension and its comparisons with the healthy normotensive, non-diabetic controls and also comparing their level among the diabetic retinopathy severity groups.
Materials and Methods: Forty five (45) patients of newly diagnosed type II diabetics with retinopathy and twenty (20) age and sex matched healthy non-diabetic & normotensive individuals of age between 20-65 were selected as the controls. In all cases and controls Fundoscopy was examined by ophthalmologist and severity of retinopathy was graded according to International clinical Diabetic retinopathy Disease severity scale. Complete blood counts (CBC), renal function test (RFT), liver function test (LFT), plasma glucose fasting and postprandial, HbA1c,urine routine/microscopy, 12 lead ECG were done all the cases and controls. Serum VEGF and Apo-A1 level was estimated using ELISA kit. The statistical analysis was done using SPSS for Windows version 16.0 software. For comparing two group of mean Students ‘t’ test and Mann-Whitney U test was used to compare VEGF and APO-A1 in the groups. The p value was considered as statistically significant when it is <0.05.
Results: In our study, males were slightly higher in number in all the groups. In our study, the maximum number of diabetic patients with retinopathy were in the age range of 51-60 years. In the present study FBS, PPBS, HbA1c, VEGF, APO-A1 were significantly elevated in the diabetic patients with retinopathy than in the control group. Significant positive correlation was seen between serum VEGF level and HBA1c.Apo-A 1 was significantly low in moderate NPDR group compared to mild NPDR and significantly low in PDR as compared to moderate NPDR.
Conclusion: In our study we have shown that serum VEGF level represents very well with the severity of retinopathy. It can be a potential tool for diabetic retinopathy early detection and probable severity prediction. Serum Apo-A1 is significantly lower in more severe retinopathy group, suggesting its protective role. In our region data regarding these two marker are scanty and these results should be validated in larger study population.
Pages: 01-05  |  164 Views  8 Downloads
How to cite this article:
Arunava Sarkar, Ranjan Bhattanagar, Ravi Tandon. A study of serum vascular endothelial growth factor and APO-A1 in diabetes mellitus with retinopathy. Pharma Innovation 2020;9(10):01-05.
The Pharma Innovation Journal